News  >  Breaking News  >  Suzhou Ribo Lands $39 Million B Round for siRNA Portfolio

Suzhou Ribo Lands $39 Million B Round for siRNA Portfolio

By Editing NAI
03/17/2017 6:50 p.m.

Suzhou Ribo Life Science, a company focused on small interfering RNA drugs, raised $39 million in a B round led by China's State Development and Investment Corporation. Founded in 2007, Ribo is developing siRNA drugs for hepatitis B, hyperlipidaemia and liver cancer. In 2012, Ribo formed a China JV with US-based Quark Pharma, also a siRNA company. Three years later, the CFDA approved the JV's Ischemic Optic Neuropathy siRNA drug for use in China.

Source: ChinaBio Today



Comments

No Comments


Please to leave a comment.